Literature DB >> 10223652

Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.

A A Acheampong1, M Shackleton, D D Tang-Liu, S Ding, M E Stern, R Decker.   

Abstract

PURPOSE: To determine the ocular pharmacokinetics of cyclosporin A after topical ophthalmic administration.
METHODS: Radiolabled cyclosporin A in either a castor oil-in-water emulsion or a corn oil ointment was applied to the eyes of beagle dogs or albino rabbits using the following paradigms: (i) single doses of 0.2% emulsion to rabbits and dogs, (ii) single doses of 0.05%, 0.2%, or 0.4% emulsion to rabbits, (iii) multiple doses of 0.2% emulsion to dogs, (iv) single and multiple doses of 0.2% ointment to rabbits. The distribution of cyclosporin A was determined by measuring the distribution of radioactivity.
RESULTS: After a single dose, cyclosporin A was rapidly absorbed into the conjunctiva (Cmax: dogs, 1490 ng/g; rabbits, 1340 ng/g) and cornea (Cmax: dogs, 311 ng/g; rabbits, 955 ng/g). High concentrations (>300 ng/g) could be detected in the cornea up to 96 hours post-dose. Lower concentrations were found in the intraocular tissues, and systemic absorption was minimal. After multiple doses, there was some accumulation in the cornea, lens, lacrimal gland, and iris-cilliary body, but limited accumulation in the conjunctiva and sclera. Ocular tissue concentrations of cyclosporin A increased with increasing dose concentration; proportionally in lacrimal gland and intraocular tissues; less than proportionally in conjunctiva and cornea. The pharmacokinetic profile of the cyclosporin A corn oil ointment was similar to that of the emulsion.
CONCLUSIONS: Topical ophthalmic cyclosporin A penetrated into extraocular tissues at concentrations adequate for local immunomodulation while penetration into intraocular tissues was much less and absorption into the blood was minimal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223652     DOI: 10.1076/ceyr.18.2.91.5381

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  13 in total

Review 1.  Wounding the cornea to learn how it heals.

Authors:  Mary Ann Stepp; James D Zieske; Vickery Trinkaus-Randall; Briana M Kyne; Sonali Pal-Ghosh; Gauri Tadvalkar; Ahdeah Pajoohesh-Ganji
Journal:  Exp Eye Res       Date:  2014-03-04       Impact factor: 3.467

2.  Hyperosmolar stress induces neutrophil extracellular trap formation: implications for dry eye disease.

Authors:  Sapna Tibrewal; Yair Ivanir; Joy Sarkar; Neema Nayeb-Hashemi; Charles S Bouchard; Eunjae Kim; Sandeep Jain
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-18       Impact factor: 4.799

Review 3.  Recent advances in ophthalmic drug delivery.

Authors:  Uday B Kompella; Rajendra S Kadam; Vincent H L Lee
Journal:  Ther Deliv       Date:  2010-09

4.  High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen.

Authors:  Mohammad H Dastjerdi; Pedram Hamrah; Reza Dana
Journal:  Cornea       Date:  2009-12       Impact factor: 2.651

5.  Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery.

Authors:  Kishore Cholkar; Brian C Gilger; Ashim K Mitra
Journal:  Transl Vis Sci Technol       Date:  2015-05-01       Impact factor: 3.283

Review 6.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27

8.  Cytomegalovirus retinitis after multiple ocular surgeries in an immunocompetent patient.

Authors:  Koji Toriyama; Takashi Suzuki; Yuko Hara; Yuichi Ohashi
Journal:  Case Rep Ophthalmol       Date:  2012-10-23

9.  Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates.

Authors:  Betül N Bayraktutar; Ömur Ö Uçakhan
Journal:  Case Rep Ophthalmol       Date:  2016-03-08

10.  Cyclosporine Amicellar delivery system for dry eyes.

Authors:  Han Kang; Kwang-Ho Cha; Wonkyung Cho; Junsung Park; Hee Jun Park; Bo Kyung Sun; Sang-Min Hyun; Sung-Joo Hwang
Journal:  Int J Nanomedicine       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.